Annual Drug Patent Expirations for VITEKTA
Vitekta is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are three patents protecting this drug.
Drug patent litigation for VITEKTA.
This drug has seventy-three patent family members in thirty-four countries.
The generic ingredient in VITEKTA is elvitegravir. Additional details are available on the elvitegravir profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
